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A B S T R A C T
Purpose
We sought to characterize the pharmacokinetics (PK) and determine a tolerable dose of oral
sorafenib in patients with hepatic or renal dysfunction.
Patients and Methods
Patients were assigned to one of nine cohorts: cohort 1, bilirubin  upper limit of normal (ULN) and
AST  ULN and creatinine clearance (CC)  60 mL/min; cohort 2, bilirubin more than ULN but
 1.5 ULN and/or AST more than ULN; cohort 3, CC between 40 and 59 mL/min; cohort 4,
bilirubin more than 1.5 ULN to  3 ULN (any AST); cohort 5, CC between 20 and 39 mL/min;
cohort 6, bilirubin more than 3 ULN to 10 ULN (any AST); cohort 7, CC less than 20 mL/min;
cohort 8, albumin less than 2.5 mg/dL (any bilirubin/AST); and cohort 9, hemodialysis. Sorafenib
was administered as a 400-mg dose on day 1 for PK, and continuous daily dosing started on day 8.
Results
Of 150 registered patients, 138 patients were treated. With the exception of cohorts 6 and 7, at
least 12 patients per cohort were assessable, and the dose level with prospectively defined
dose-limiting toxicity in less than one third of patients by day 29 was considered tolerable. No
significant associations between the sorafenib PK and cohort were found.
Conclusion
We recommend the following empiric sorafenib starting doses by cohort: cohort 1, 400 mg twice
a day; cohort 2, 400 mg twice a day; cohort 3, 400 mg twice a day; cohort 4, 200 mg twice a day;
cohort 5, 200 mg twice a day; cohort 6, not even 200 mg every third day tolerable; cohort 7, not
defined; cohort 8, 200 mg each day; and cohort 9, 200 mg each day.
J Clin Oncol 27:1800-1805. © 2009 by American Society of Clinical Oncology
INTRODUCTION
Raf, which is an essential serine/threonine kinase
constituent of the mitogen-activated protein kinase
signaling pathway and a downstream effector of the
central signal transduction mediator Ras, is acti-
vated in a wide range of human malignancies and is
therefore recognized as a strategic target for thera-
peutic drug development.1 Sorafenib (formerly BAY
43-9006), an orally active multikinase inhibitor
with effects on tumor cell proliferation and tumor
angiogenesis, was initially identified as a Raf
kinase inhibitor.2 It also inhibits vascular endo-
thelial growth factor receptors 1, 2, and 3; platelet-
derived growth factor receptor ; FMS-like
tyrosine kinase 3; c-Kit protein; and RET receptor
tyrosine kinase.2,3 Sorafenib is approved by the
United States Food and Drug Administration and
other global health authorities for the treatment of
renal and hepatocellular carcinomas and has also
demonstrated activity in a number of other
malignancies.4-6 As in the development of other
new drugs, sorafenib was initially tested in pa-
tients with adequate hepatic and renal function,
and the recommended continuous daily dose is 400
mg twice a day for such patients.7-9 The most com-
mon side effects include hand-foot skin reactions,
diarrhea, fatigue, rash, and hypertension.4-9 Sor-
afenib is primarily metabolized in the liver (pre-
dominantly by CYP3A4). Urinary excretion is a
minor ( 20%) route of elimination. We hypothe-
sized that the pharmacokinetics and tolerability of
sorafenib would be affected by hepatic dysfunction,
but not by renal dysfunction. Because patients with
malignancies often present with abnormal hepatic
or renal function, the objectives of this study were to
characterize the pharmacokinetics and to determine
tolerable starting doses of sorafenib in such patients.
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PATIENTS AND METHODS
Eligibility Criteria
Patients were eligible if they had pathologically documented solid tu-
mors, multiple myeloma, or non-Hodgkin’s lymphoma for which standard
curative or palliative measures did not exist. Patients had to be  18 years of
age with an Eastern Cooperative Oncology Group performance status of 0 to 2.
Required laboratory values at entry included an absolute neutrophil count
 1,500/L and platelet count  75,000/L. Prior therapies (including chem-
otherapy, surgery, and radiation) had to be completed at least 4 weeks before
enrollment. The study had to be approved by the institutional review board of
each participating institution, and all patients gave written informed consent.
Exclusion Criteria
Patients who were pregnant or lactating were excluded. Concomitant
medications known to cause hepatic or renal toxicity were not allowed on
study. Other exclusion criteria included gastrointestinal tract disease resulting
in an inability to take oral medication, HIV-positive patients on antiretroviral
therapy, therapeutic anticoagulation, evidence of biliary or renal obstruction,
and treatment with cytochrome P450 enzyme-inducing antiepileptic drugs,
rifampin, or St John’s wort.
Cohort Definitions
No widely accepted guidelines defining organ dysfunction in patients
with cancer were available when this study was designed. Our aim was to use
laboratory values that are routinely available in clinical practice, such as serum
total bilirubin, AST, albumin, and creatinine. The creatinine clearance was
estimated using the Cockcroft and Gault formula.10 The study included a
cohort with normal organ function (cohort 1) and eight cohorts with increas-
ing severity of hepatic dysfunction (cohorts 2, 4, 6, and 8) or renal dysfunction
(cohorts 3, 5, 7, and 9) as defined in Table 1. Patients who fit into more than
one of these cohorts (eg, elevated bilirubin and decreased creatinine clearance)
were not eligible for this study, except for cohort 8, for which patients had
creatinine clearance  60 mL/min and any bilirubin/AST (including biliru-
bin/AST  upper limit or normal [ULN]).
Treatment
The study was conducted in two parts. In part 1, all patients received a
single oral test dose of 400 mg of sorafenib on day 1 to assess the pharmacoki-
netics by type and severity of organ impairment. Part 2 started on day 8 and
was designed as a phase I dose-escalation study to evaluate the toxicity of
continuous oral dosing of sorafenib by cohort. Cohort and dose level assign-
ment occurred before the start of treatment on day 8 after a discussion with the
study chair, which included a review of the eligibility and exclusion criteria and
cohort assignment in parts 1 and 2. The initial dose (level 1) of sorafenib
depended on cohort: cohort 1, 400 mg twice a day; cohorts 2 and 3, 200 mg
twice a day; cohorts 4 and 5, 200 mg each day; and cohorts 6 through 9, 200 mg
every other day. If dose-limiting toxicity (DLT) was reached at dose level 1 in
cohorts 6 through 9, further patients were to be treated with sorafenib 200 mg
every third day (dose level 1). Escalation to the next dose level occurred in a
new group of patients if the maximum-tolerated dose (MTD) had not been
reached and all patients in a cohort had been treated for at least 3 weeks (days
8 through 29). The sorafenib dose was escalated by cohort in 200-mg steps to
400 mg twice a day. Sorafenib was manufactured by Bayer Pharmaceuticals
(West Haven, CT) and distributed by the National Cancer Institute Pharma-
ceutical Management Branch as 200-mg tablets.
Required Data
Patient registration and data collection were managed by the Cancer and
Leukemia Group B (CALGB) Statistical Center. Before registration and weekly
during the first month of treatment, details of history and physical examina-
tion, complete blood cell counts with differential, and pertinent chemistry
results for hepatic and renal function were collected. The chemistry values
determining cohort assignment were required twice within 10 days before
registration. Data were prospectively recorded to calculate the Child-Pugh
score.11 During months 2 and 3, history and physical examinations were done
every 4 weeks and laboratory studies were done every 2 weeks. The Common
Terminology Criteria for Adverse Events, version 3.0, and the Response Eval-
uation Criteria in Solid Tumors from the National Cancer Institute were
used.12 Data quality was ensured by careful review of data by CALGB Statistical
Center staff and by the study chair.
DLT
Because there are no widely accepted rules to define DLT in patients with
abnormal liver or renal function tests at entry on trial, our definitions were
empiric, but they were prospectively defined in the protocol. For cohorts 2, 4,
6, and 8, an increase in AST or alkaline phosphatase  2.5 baseline or an
increase in total bilirubin  1.5 baseline were considered dose-limiting
hepatic toxicity unless unequivocally caused by tumor progression as evi-
denced by imaging studies, and a reduction of creatinine clearance more than
10 mL/min was defined as DLT. For cohorts 3, 5, 7, and 9, a reduction of
creatinine clearance more than 20 mL/min was considered dose-limiting renal
toxicity, and elevations in AST or alkaline phosphatase  5 ULN or total
bilirubin  2.5 ULN were defined as DLT. Other grade 3 or worse nonhe-
matologic toxicity was defined as DLT. Grade 3 or worse nausea, vomiting,
diarrhea, or anorexia despite optimal supportive care were also considered
DLT. Grade 4 neutropenia and grade 4 thrombocytopenia were defined
as DLT.
Dose-Escalation Rules
Dose escalation to the next dose level occurred in groups of patients
when the MTD was not reached and after patients in a cohort had been treated
for at least 3 weeks with continuous daily dosing of sorafenib. If none of three
patients developed DLT, three patients were entered at the next dose level. If
two or more patients of three experienced DLT, dose escalation was stopped
and this dose level was the highest administered dose. If one of three patients
developed DLT, at least three more patients were entered at this dose level. If
none of these three additional patients experienced DLT, we proceeded to the
next dose level. If one or more of these three additional patients experienced
DLT, then dose escalation was stopped, and this dose was the highest admin-
istered dose. The MTD was prospectively defined as the dose level at which no
more than one of six patients had DLT. The objective was to assess patients for
DLT in the first 4 weeks on protocol. Therefore, patients who discontinued
protocol therapy within the first 4 weeks for reasons other than toxicity were
replaced and not considered in the determination of MTD. We planned to
treat 12 patients in cohort 1 and at least six patients in each of the other cohorts.
The protocol allowed enrollment of more than six patients per dose level to
clarify the toxicity pattern.
Table 1. Cohort Definitions
Cohort Description Hepatic Renal
Normal organ function Cohort 1: Total bilirubin  ULN and AST  ULN and CrCl  60 mL/min
Mild dysfunction Cohort 2: Bilirubin  ULN but  1.5 ULN and/or AST  ULN Cohort 3: CrCl between 40 and 59 mL/min
Moderate dysfunction Cohort 4: Bilirubin  1.5 ULN to  3 ULN and any AST Cohort 5: CrCl between 20 and 39 mL/min
Severe dysfunction Cohort 6: Bilirubin  3 ULN to 10 ULN and any AST Cohort 7: CrCl  20 mL/min
Very severe dysfunction Cohort 8: Albumin  2.5 mg/dL, any bilirubin, and any AST Cohort 9: Hemodialysis, any CrCl
Abbreviations: ULN, upper limit of normal; CrCl, creatinine clearance.
Sorafenib in Hepatic or Renal Dysfunction
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Pharmacokinetics
Blood samples were obtained at baseline and at 1, 2, 3, 4, 6, and 24 hours
after the 400-mg test dose of sorafenib on day 1. After centrifugation, the
plasma was separated and frozen and then shipped to the CALGB coordinat-
ing office at the Ohio State University. The plasma concentrations of sorafenib
and its N-oxide, desmethyl, and N-oxide desmethyl metabolites were mea-
sured by high-performance liquid chromatography with tandem mass spec-
trometry by Bayer Pharmaceuticals (Hamden, CT).13 The fraction of sorafenib
not bound to plasma proteins was measured in vitro by Bayer Pharmaceuticals
(Wuppertal, Germany) with C14-labeled sorafenib in patients’ plasma (sample
at 4 hours after test dose) according to a published method.14 Sorafenib
pharmacokinetic parameters were estimated using Adapt II software15 and
maximum a posteriori Bayesian estimation methods. A two-compartment
linear model parameterized using clearances and incorporating first order
absorption with an absorption delay was applied to estimate the total apparent
oral clearance of sorafenib. Prior parameter distributions were provided by
Bayer Pharmaceuticals (West Haven, CT). The area under the curve (AUC)
was calculated using the equation: AUC  dose/apparent clearance. The
N-oxide metabolite AUC0-24 was determined by the linear trapezoidal rule.
Statistical Analyses
Statistical analyses were performed by CALGB statisticians. The mar-
ginal distributions of the pharmacokinetic parameters were summarized
quantitatively using standard measures of central tendencies, location, and
spread (eg, mean, median, standard deviation). The distribution of AUC is
depicted graphically using dot plots rather than box plots because of the small
number of patients within each cohort.16 The discrepancies among the distri-
butions of AUC of sorafenib with respect to factors (eg, cohorts) were assessed
using the Kruskal-Wallis test.17 Inference for the associations between AUC
and continuous measurements (eg, creatinine clearance) were carried out
using the Spearman rank correlation test.17 The exact two-sided P values were
approximated using B  10,000 permutation replicates for the rank tests. The
statistical analyses and plots were produced using the statistical computing
environment R (version 2.7.1)18 statistical environment including package
coin19 for generating the conditional permutation P values.
RESULTS
Between January 2005 and February 2007, 150 patients were enrolled.
Of these, 12 patients never started therapy and were excluded from all
analyses. The demographics of the 138 treated patients were as follows:
male sex, n  95, female sex, n  43; median age, 60 years (range, 21 to
85 years); white, n106, African America, n21, Asian, n6, other,
n  5; and performance status of 0, n  32, 1, n  83, 2, n  23. Of the
138 patients in part 1, 124 patients proceeded into part 2 and 14 did
not (13 with hepatic and one with renal dysfunction) because of their
deteriorating clinical condition. The distribution of patients in the
various cohorts by part was as follows: cohort 1, part 1, n  12, part 2,
n  16; cohort 2, part 1, n  14, part 2, n  12; cohort 3, part 1, n  18,
part 2, n  16; cohort 4, part 1, n  21, part 2, n  17; cohort 5, part 1,
n  14, part 2, n  13; cohort 6, part 1, n  13, part 2, n  11; cohort
7, part 1, n  5, part 2, n  4; cohort 8, part 1, n  24, part 2, n  18;
and cohort 9, part 1, n17, part 2, n17. Seventeen patients (10 with
hepatic and seven with renal dysfunction) changed cohort assignment
between part 1 and part 2 because of changes in their hepatic or renal
function tests.
Pharmacokinetic results for sorafenib were available for 124
(90%) of the 138 treated patients. The AUC of the major metabolite,
N-oxide-sorafenib, could be estimated in 100 patients (72%). Selected
pharmacokinetic results for sorafenib and its N-oxide metabolite are
summarized by cohort in Table 2. Figures 1 and 2 graphically depict
the observed AUCs of sorafenib and its N-oxide metabolite by cohort.
There was no (P .05) significant evidence that the AUCs of sorafenib
or its N-oxide metabolite were associated with cohort. Of the 72
patients in the hepatic cohorts, the Child-Pugh scores for 62 patients
were available, and 53 of these patients had pharmacokinetic data. The
analysis of the sorafenib AUC against the Child-Pugh scores and the
Table 2. Pharmacokinetic Results
Variable and Statistic Cohort 1
Hepatic Cohorts Renal Cohorts
2 4 6 8 3 5 7 9
Sorafenib AUC, mg  h/L
No. 12 13 16 12 19 18 12 5 17
Mean 61.6 99.8 166.8 97.3 106.4 80.2 80.4 61.7 212.4
SD 42.7 71.1 304.5 109.3 85.5 60.8 36.0 44.3 553.9
Median 51.3 85.5 79.0 58.5 77.1 59.9 79.4 56.9 93.7
N-oxide metabolite AUC, mg  h/L
No. 10 8 15 7 16 15 11 5 13
Mean 3.5 3.9 3.1 0.9 2.3 3.0 5.3 1.3 4.6
SD 4.8 5.7 4.0 1.1 2.6 2.5 4.1 1.0 5.3
Median 1.8 2.3 1.1 0.5 1.4 3.3 3.8 1.7 2.3
Sorafenib fraction unbound
No. 12 13 16 12 19 18 12 5 17
Mean 0.0058 0.0055 0.0043 0.0046 0.0038 0.0055 0.0059 0.0068 0.0064
SD 0.0025 0.0020 0.0021 0.0017 0.0015 0.0018 0.0021 0.0033 0.0022
Median 0.0053 0.0058 0.0043 0.0048 0.0034 0.0059 0.0065 0.0062 0.0059
Sorafenib AUC of fraction unbound, mg  h/L
No. 12 13 16 12 19 18 12 5 17
Mean 0.4 0.6 1.0 0.4 0.4 0.5 0.5 0.5 1.6
SD 0.3 0.6 2.5 0.5 0.3 0.4 0.3 0.6 4.5
Median 0.2 0.4 0.3 0.3 0.3 0.4 0.3 0.4 0.4
Abbreviations: AUC, area under the curve; SD, standard deviation.
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bilirubin concentrations for the patients in the hepatic cohorts dem-
onstrated a lack of significant relationships. Although there was no
significant relationship between the AUC of the N-oxide metabolite
and the Child-Pugh scores, higher bilirubin concentrations were asso-
ciated (Spearman correlation test, P  .022) with lower AUCs of the
metabolite in the hepatic cohorts. For the 54 patients in the renal
cohorts, no significant relationships were identified between creati-
nine clearance and the AUC of sorafenib or the N-oxide metabolite.
Because sorafenib is bound to plasma proteins (albumin, - and
-globulin, and low-density lipoprotein), the unbound fractions (Fig
3) were compared between the patients with normal hepatic and renal
function (cohort 1), hepatic dysfunction (cohorts 2, 4, 6, and 8), and
renal dysfunction (cohorts 3, 5, 7, and 9), and a significant (Kruskal-
Wallis test, P  .001) association was found; however, this was not
explained by the albumin or bilirubin concentrations. Patients with
hepatic dysfunction were significantly (Kruskal-Wallis test, P .0009)
younger than patients with renal dysfunction; however, there were no
significant associations between age and the AUCs of sorafenib or the
N-oxide metabolite.
Of the 16 patients in cohort 1 treated in part 2 of the study, 14
patients were assessable and two patients had DLT (one grade 3 ab-
dominal pain and one grade 3 rash). Table 3 contains the phase I
experience for the hepatic cohorts. The main reason why patients were
not assessable was their inability to take sorafenib continuously for 3
weeks as a result of progressive malignant disease with clinical deteri-
oration. When two of two patients in cohort 6 at the starting dose level
1 developed DLT, nine patients were entered on dose level 1; six of
these patients were assessable and three had DLT. Thus in cohort 6,
even 200 mg of sorafenib every third day was intolerable based on our
definitions of DLT. The events of DLT in the hepatic cohorts included
increase in total bilirubin  1.5 baseline (n  10); grade 3 diarrhea
despite optimal supportive care (n  1); grade 3 fatigue (n  1); grade
3 fatigue and creatinine clearance reduction more than 10 mL/min
(n  1); and grade 3 hypertension (n  1). One of the patients with an
increase in total bilirubin  1.5 baseline had previously treated
small-cell lung cancer and experienced fatal tumor lysis syndrome
while taking sorafenib. Table 3 also summarizes the phase I experience
for the renal cohorts. Patients with an estimated creatinine clearance
less than 20 mL/min were infrequently encountered in clinical prac-
tice, and only four patients were enrolled in cohort 7. The DLT in the














































































Fig 3. Dot plot of the fraction of sorafenib unbound to plasma proteins
by cohort.
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event each of the following: grade 3 abdominal pain; grade 3 fatigue;
grade 3 nausea and vomiting despite optimal supportive care; grade 3
hand-foot skin reaction; grade 3 congestive heart failure; and grade 4
hemorrhage into brain metastasis. Dose level 4 of sorafenib 400 mg
twice a day was not reached in either hepatic or renal cohorts 6
through 9.
A wide variety of neoplasms were represented in this phase I
study; the categories with at least 10 accruals included renal (n  32),
colorectal (n  23), and hepatocellular (n  17) carcinomas. Partial
responses were observed in four patients: one each with papillary
thyroid cancer (cohort 2, dose level 2), hepatocellular cancer (cohort
8, dose level 1), prostate cancer (cohort 9, dose level 2), and renal
cancer (cohort 9, dose level 3).
DISCUSSION
Part 1 of this study tried to identify differences in the pharmacokinet-
ics after a single oral test dose of 400 mg of sorafenib in patients with
varying degrees of hepatic or renal dysfunction. In contradiction to
our a priori hypothesis, no significant associations between the AUC
of sorafenib or its major metabolite and cohort were apparent.
Part 2 of the study was successful because the phase I results
summarized in Table 3 support the notion that patients with moder-
ate to severe hepatic and renal dysfunction (cohorts 4 through 9)
cannot tolerate the dose of 400 mg twice a day that is recommended
for patients with normal organ function. Our study was intended to
inform the clinician about the starting dose of sorafenib in patients
with hepatic or renal dysfunction based on readily available labo-
ratory information, and we recommend the following empiric
starting doses by cohort (Tables 1 and 3 for reference): cohort 1, 400
mg twice a day; cohort 2, 400 mg twice a day; cohort 3, 400 mg twice a
day; cohort 4, 200 mg twice a day; cohort 5, 200 mg twice a day; cohort
6, not even 200 mg every third day was tolerable; cohort 7, not defined;
cohort 8, 200 mg each day; and cohort 9, 200 mg each day. We would
like to emphasize that clinicians should consider dose escalation in an
individual patient if the drug is well tolerated.
Treatment with sorafenib was associated with dose-limiting ele-
vation in bilirubin concentrations over baseline in 10 patients with
hepatic dysfunction, but not in patients with renal dysfunction. This
may have been due to the inhibition of uridine disphosphate-
glucuronosyl-transferase (UGT1A1) by sorafenib. Otherwise, sor-
afenib was well tolerated, and no unexpected toxicities were
encountered. Whereas the majority of patients with renal dysfunction
were assessable, many patients with hepatic dysfunction were unable
to complete the first 3 weeks of continuous dosing and were deemed
unassessable per protocol. This is consistent with studies classifying
prognostic comorbidity in longitudinal studies. For instance, the com-
monly used Charlson risk index assigns higher points for liver disease
than for renal disease.20 The worst possible risk for complications in
the Charlson index is a metastatic solid tumor plus moderate or severe
liver disease (6  3 points; very high risk  5 points). Abou-Alfa et al21
reported no significant differences in sorafenib pharmacokinetics be-
tween patients with Child-Pugh A and B scores. We were able to
corroborate this finding.
A limitation of this study is that the set of definitions for hepatic
and renal dysfunction is still based on standard clinical laboratory
values (ie, bilirubin and creatinine) rather than more involved mea-
surements of hepatic and renal function; however, the current defini-
tions have evolved considerably from prior CALGB phase I and
pharmacokinetic organ dysfunction trials with paclitaxel, gemcitab-
ine, irinotecan, and erlotinib that were conducted in far fewer cohorts
and patients.22-26 In the study of erlotinib,26 our findings in a cohort
of three patients suggested that low albumin was an indicator of
more severe liver dysfunction than hyperbilirubinemia. Cohort 8
of the current study confirmed that low albumin warrants spe-
cial consideration.
Table 3. Phase I Experience by Cohort and Dose Level
Cohort and Variable
Dose Level
1 1 2 3
Hepatic cohorts
Cohort 2 — —
No. of patients entered 5 7
No. of patients assessable 5 7
No. of patients with DLT 1 1
Dose of sorafenib, mg 200 bid 400 bid
Cohort 4 —
No. of patients entered 6 10 1
No. of patients assessable 6 6 1
No. of patients with DLT 1 1 1
Dose of sorafenib, mg 200 qd 200 bid 400 bid
Cohort 6
No. of patients entered 9 2
No. of patients assessable 6 2
No. of patients with DLT 3 2
Dose of sorafenib, mg 200 q3d 200 qod 200 qd 200 bid
Cohort 8
No. of patients entered — 4 9 6
No. of patients assessable 4 6 5
No. of patients with DLT 0 1 3
Dose of sorafenib, mg 200 qod 200 qd 200 bid
Renal cohorts
Cohort 3
No. of patients entered 6 10 —
No. of patients assessable 6 9
No. of patients with DLT 0 2
Dose of sorafenib, mg 200 bid 400 bid
Cohort 5
No. of patients entered 3 6 4
No. of patients assessable 3 6 3
No. of patients with DLT 0 1 2
Dose of sorafenib, mg 200 qd 200 bid 400 bid
Cohort 7
No. of patients entered 4
No. of patients assessable 4
No. of patients with DLT 1
Dose of sorafenib, mg 200 qod 200 qd 200 bid
Cohort 9
No. of patients entered 3 6 8
No. of patients assessable 3 5 6
No. of patients with DLT 0 0 2
Dose of sorafenib, mg 200 qod 200 qd 200 bid
Abbreviations: DLT, dose-limiting toxicity; bid, twice a day; qd, each day; q3d,
every 3 days; qod, every other day.
Recommended starting dose level.
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